Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,476 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE.
Weitz JI, Farjat AE, Ageno W, Turpie AGG, Haas S, Goto S, Goldhaber SZ, Angchaisuksiri P, Gibbs H, MacCallum P, Carrier M, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE Investigators. Weitz JI, et al. Among authors: haas s. J Thromb Haemost. 2021 Dec;19(12):3031-3043. doi: 10.1111/jth.15520. Epub 2021 Sep 16. J Thromb Haemost. 2021. PMID: 34487616 Free article.
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
Kakkar VV, Boeckl O, Boneu B, Bordenave L, Brehm OA, Brücke P, Coccheri S, Cohen AT, Galland F, Haas S, Jarrige J, Koppenhagen K, LeQuerrec A, Parraguette E, Prandoni P, Roder JD, Roos M, Rüschemeyer C, Siewert JR, Vinazzer H, Wenzel E. Kakkar VV, et al. Among authors: haas s. World J Surg. 1997 Jan;21(1):2-8; discussion 8-9. doi: 10.1007/s002689900185. World J Surg. 1997. PMID: 8943170 Clinical Trial.
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Gräve M, Patek F, Drexler M, Siemens HJ, Harenberg J, Weidinger G, Brom J, Haas S; TH-4 Study Group. Riess H, et al. Among authors: haas s. Thromb Haemost. 2003 Aug;90(2):252-9. doi: 10.1160/TH02-09-0061. Thromb Haemost. 2003. PMID: 12888872 Clinical Trial.
[Home treatment for deep vein thrombosis: pros and cons].
Bauersachs R, Haas S, Schellong S. Bauersachs R, et al. Among authors: haas s. Hamostaseologie. 2004 Aug;24(3):167-72. doi: 10.1267/hamo04030167. Hamostaseologie. 2004. PMID: 15314701 Review. German.
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P; ODIXa-HIP Study Investigators. Eriksson BI, et al. Among authors: haas s. Circulation. 2006 Nov 28;114(22):2374-81. doi: 10.1161/CIRCULATIONAHA.106.642074. Epub 2006 Nov 20. Circulation. 2006. PMID: 17116766 Clinical Trial.
1,476 results